Arogyavardhini Vati Benefits, Ingredients Treatment of liver problems

arogyavardhini ayurgreen
arogyavardhini ayurgreen

ఆరోగ్య వర్ధిని వటి ఆయుర్వేద వైద్యుని వద్ద ఉండవలసిన ముఖ్య ఔషదమ్.దీనిని రసాయన ఔషదంగా చెప్పవచ్చును.చర్మ వ్యాధులు తగ్గించటంలోను కాలేయంను ఆరోగ్యంగా ఉంచడం లోనూ,గ్యాస్ సమస్య తగ్గించటం లోనూ ముఖ్య పాత్ర వహిస్తుంది.దీనిలో ఉండే పాదరసం,గంధకం,లోహ భస్మ,అబ్రక భస్మ,తామ్ర భస్మ,శిలాజిత్ లాంటి గొప్ప ఔషదాలు ఉండటం వల్ల శరీరాన్ని ఆరోగ్యంగా ఉంచుతుంది.దీర్ఘకాలిక చర్మ వ్యాధులు ను తగ్గించును.

Ingredients:

  • త్రిఫల
  • శిలాజిత్
  • గుగ్గులు
  • చిత్రమూలం(చిత్రిక)( Plumbago Zeylanica)
  • కటుకరోహిణి(కుటికి)(Picrorhiza Kurroa)
  • గంధకం
  • పాదరసం
  • లోహభస్మ
  • అబ్రకభస్మ
  • తామ్రభస్మ
  • వేప ఆకు రసం
arogyavardhini ayurgreen
arogyavardhini ayurgreen

తగ్గించే వ్యాధులు:

  1. అన్నీ రకాల చర్మ వ్యాధులను తగ్గించును.
  2. కాలేయంను ఆరోగ్యంగా ఉంచును.
  3. కొలెస్ట్రాల్ ను తగ్గించును.
  4. హెపటైటిస్ సమస్యలను తగ్గించును.
  5. గజ్జి,దురద,తామర,బొల్లి,సోరియాసిస్ లాంటి సమస్యలను తగ్గించును.
  6. జీర్ణ శక్తిని పెంచి గ్యాస్త్రిక్ సమస్యను తగ్గించును.
  7. జాండీస్, ప్యాటిలివర్ సమస్యను తగ్గించును.
  8. Acute And Chronic fever
  9. Used In Loss Of Appetite Borborygni

అనుపానం:

  • సారిబాద్యసావ తో ఆరోగ్యవర్ధిని తీసుకుంటే గజ్జి,తామర తగ్గును.
  • కుమారసావ తో దీనిని తీసుకుంటే కడుపుఉబ్బరం,వాంతి,మలబద్దకం,జీర్ణసమస్యలు తగ్గును.
  • పునర్నావాది కాషాయంతో  వాడితే గుండె సమస్య,గుండె పెరుగుదల తగ్గును.
  • శృంగిభస్మతో సేవిస్తే ఊపిరితిత్తుల యందు నీటిని తొలగించును.
  • శిలాసిందూర, బావంచాల చూర్ణం అనుపానం తో వాడితే శరీర బరువును తగ్గించును.

Side effects:

— గర్భవతులు, తలతిరుగుట లాంటి సమస్యలు , విపరీతమైన దాహం ఉన్నవారు దీనిని వాడరాదు. వాడవలసి వస్తే వైద్యుని పర్యవేక్షణలో వాడాలి.

Dose:

250 mg పరిమాణం గల మాత్రలు రెండు పూటలు భోజనం తరువాత గోరువెచ్చని నీటితో వెయ్యాలి.10 నుంచి 18 సంవత్సరం వయస్సు వారు 125 mg పరిమాణం లో వాడాలి

Reference:

–Rasratan Samucheya

–Rasendrasara Sangraha

Research:

    1. Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role. Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. Total of 108 patients were screened at CGHS Ayurvedic Hospital, New Delhi.

    Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder (5 g, BD) for 3 weeks and then Arogyavardhini Vati (500 mg, BD) for 4 weeks were prescribed to the patients. The primary efficacy endpoint was reduction in serum total cholesterol, LDL, triglycerides, and increased HDL levels. Secondary endpoints included reduction in serum C-Reactive Protein (CRP) and blood glucose levels. Safety assessments included hepatic function (aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, and β2 microglobulin), renal function (urea and creatinine and NGAL) tests, and urine mercury level.

    The study was completed by 87 patients. The male and female patients were 65.5% (57/87) and 34.5% (30/87), respectively. There was a significant reduction in total cholesterol, LDL, triglycerides, CRP, and blood glucose. However, raised HDL level was also observed. Safety assessment results showed no significant change in serum ALT, AST, ALP and bilirubin, urea, creatinine β2 microglobulin, and NGAL levels at the end of study as compared to the baseline levels. In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia.

  1. Arogyavardhini vati at doses of 50, 250 and 500 mg/kg (1, 5 and 10 times of human equivalent dose respectively), mercury chloride (1 mg/kg) and normal saline were administered orally to male Wistar rats for 28 days. Behavioral parameters were assessed on day 1, 7th, 14th and 28th using Morris water maze, passive avoidance, elevated plus maze and rota rod. Biochemical parameters (acetyl-cholinesterase activity, malondialdehyde, reduced glutathione), histopathology and mercury level in brain, liver, kidney were assessed at the end of the experiment.
  2. PCM produced significantly impaired the liver and kidney functions as assessed through an increase in liver and kidney marker enzymes. Arogyavardhini-treated group significantly (P = 0.05) prevented this hepatotoxicity and strongly supported by histopathological examinations that revealed AVR shows the protection of liver tissue from PCM-induced hepatotoxicity.
  3. Arogyavardhini vati significantly decreased serum cholesterol, triglyceride, LDL, and C-reactive protein (CRP) and significantly increased serum HDL in a dose-dependent manner. Decreased MDA and increased GSH levels in liver were observed at all doses of Arogyavardhini vati (50, 100, 200 mg/kg) and fenofibrate-treated groups when compared with Triton-treated group. Atherogenic Index (AI) level was significantly decreased in fenofibrate and Arogyavardhini vati (200 mg/kg) treated rats when compared with normal control.
  4. Liver disease is the tenth most common cause of death in India as per the World Health Organization and may affect every one in Five Indians. In spite of consistent human effort and drug discovery, modern drug has very little to offer. Nonetheless, Ayurveda classical proprietary and patented formulations have shown promising results. The present study provides a general review of the Ayurveda products along with pharmacological actions of herbal medicines. Arogyavardhini vati, Liv 52 are the highest prescribing medicines in liver disorders. Curcuma longa, Phyllanthus niruri, Tephrosia purpurea, Picrorrhiza kurroa, Swertia chirayata are the commonest single herb used by the herbalist and Ayurveda physician in the treatment of various liver disorders. An attempt has been made to compile classical, proprietary and patented Ayurveda products. This may be useful to the clinicians, professionals, scientists and scholars working in the field of Ayurveda for new product development.

 

Leave a comment

Your email address will not be published. Required fields are marked *